{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["PF-08634404"],["PF-08634404","enfortumab vedotin"]],"indication":"locally advanced or metastatic urothelial cancer","name":"Symbiotic-GU-06","nct_id":"NCT07421700","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=symbiotic-gu-06-nct07421700. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants with previously treated LA/mUC will receive PF-08634404 administered intravenously as monotherapy.","label":"Cohort A","type":"EXPERIMENTAL"},{"description":"Participants with untreated LA/mUC will receive PF-08634404 in combination with enfortumab vedotin","label":"Cohort B","type":"EXPERIMENTAL"}],"collaborators":["Astellas Pharma Inc"],"completion_date":{"date":"2028-09-25","type":"ESTIMATED"},"conditions":["Urothelial Cancer","Advanced/Metastatic Urothelial Cancer","Urothelial Carcinoma"],"enrollment":{"count":132,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"PF-08634404","otherNames":["SSGJ-707"],"type":"BIOLOGICAL"},{"name":"Enfortumab Vedotin","otherNames":["PF-08046042","ASG-22CE","PADCEV"],"type":"BIOLOGICAL"}],"last_update":"2026-10-08","lead_sponsor":"Pfizer","official_title":"AN INTERVENTIONAL PHASE 1B/2, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, ANTITUMOR ACTIVITY, AND PHARMACOKINETICS OF PF 08634404 MONOTHERAPY OR IN COMBINATION WITH ENFORTUMAB VEDOTIN IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2027-12-28","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Confirmed Objective Response Rate (ORR) by investigator","timeFrame":"Up to approximately 3 years"},{"measure":"Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","timeFrame":"Through 90 days after the last study intervention; Up to approximately 3 years"},{"measure":"Number of participants with dose limiting toxicity (DLT) in Part 1 of Cohort B","timeFrame":"Through 90 days after the last study intervention; Up to approximately 3 years"}],"references":[],"start_date":{"date":"2026-03-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer","url":"https://clinicaltrials.gov/study/NCT07421700"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/symbiotic-gu-06-nct07421700"}